MX2019008815A - Sintesis de un inhibidor de tirosina quinasa de bruton. - Google Patents

Sintesis de un inhibidor de tirosina quinasa de bruton.

Info

Publication number
MX2019008815A
MX2019008815A MX2019008815A MX2019008815A MX2019008815A MX 2019008815 A MX2019008815 A MX 2019008815A MX 2019008815 A MX2019008815 A MX 2019008815A MX 2019008815 A MX2019008815 A MX 2019008815A MX 2019008815 A MX2019008815 A MX 2019008815A
Authority
MX
Mexico
Prior art keywords
bruton
synthesis
tyrosine kinase
kinase inhibitor
inhibitor
Prior art date
Application number
MX2019008815A
Other languages
English (en)
Inventor
Chen Wei
Goldman Erick
Benhaim Cyril
Horvath Andras
Pye Philip
S Smyth Mark
J Verner Erik
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2019008815A publication Critical patent/MX2019008815A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

En la presente memoria se describe la síntesis de inhibidor de tirosina quinasa de Bruton (Btk) de 1-((R)-3-(4-amino-3-(4-fenoxif enil)-1H-pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2- en-1-ona.
MX2019008815A 2015-01-14 2017-07-12 Sintesis de un inhibidor de tirosina quinasa de bruton. MX2019008815A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14

Publications (1)

Publication Number Publication Date
MX2019008815A true MX2019008815A (es) 2019-09-26

Family

ID=56406389

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009154A MX366827B (es) 2015-01-14 2016-01-14 Sintesis de un inhibidor de tirosina quinasa de bruton.
MX2019008815A MX2019008815A (es) 2015-01-14 2017-07-12 Sintesis de un inhibidor de tirosina quinasa de bruton.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017009154A MX366827B (es) 2015-01-14 2016-01-14 Sintesis de un inhibidor de tirosina quinasa de bruton.

Country Status (16)

Country Link
US (4) US20180009814A1 (es)
EP (1) EP3245208A4 (es)
JP (2) JP2018502077A (es)
KR (1) KR20170102887A (es)
CN (2) CN113816962A (es)
AU (2) AU2016206693A1 (es)
BR (1) BR112017015206B1 (es)
CA (2) CA2971460C (es)
HK (1) HK1246293A1 (es)
IL (3) IL308276A (es)
MA (1) MA41350A (es)
MX (2) MX366827B (es)
RU (1) RU2017128308A (es)
SG (2) SG10201906517VA (es)
WO (1) WO2016115356A1 (es)
ZA (1) ZA201704338B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3257855B1 (en) * 2015-02-12 2020-04-22 Shanghai Dude Medical Science and Technology Co., Ltd. Method for preparing ibrutinib
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
EP3661939B1 (en) * 2017-08-01 2021-07-21 Boehringer Ingelheim International GmbH Intermediate compounds and methods
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
MX2020011527A (es) 2018-05-03 2021-02-26 Juno Therapeutics Inc Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
JP6944496B2 (ja) * 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
AU2018448845B2 (en) 2018-11-09 2022-03-24 Taiho Pharmaceutical Co., Ltd. Method for producing dimethoxybenzene compound
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
MX2021014245A (es) 2019-05-21 2022-01-06 Janssen Pharmaceutica Nv Procedimientos y productos intermedios para preparar un inhibidor de btk.
KR20220011668A (ko) 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
EP4281454A1 (en) 2021-01-21 2023-11-29 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
EP1706385B1 (en) * 2003-12-23 2010-10-06 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
KR101315610B1 (ko) * 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CA2874756C (en) * 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
ES2682043T3 (es) * 2012-07-30 2018-09-18 Concert Pharmaceuticals Inc. Ibrutinib deuterado
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定***
EP3248979B1 (en) * 2015-01-21 2021-04-14 Hefei Institutes of Physical Science, Chinese Academy of Sciences Novel inhibitor of flt3 kinase and use thereof

Also Published As

Publication number Publication date
BR112017015206B1 (pt) 2023-04-11
US20220098200A1 (en) 2022-03-31
MX366827B (es) 2019-07-25
MA41350A (fr) 2017-11-21
CA2971460A1 (en) 2016-07-21
EP3245208A1 (en) 2017-11-22
EP3245208A4 (en) 2018-10-17
KR20170102887A (ko) 2017-09-12
MX2017009154A (es) 2017-10-12
JP2021035947A (ja) 2021-03-04
US20180009814A1 (en) 2018-01-11
RU2017128308A3 (es) 2019-10-24
BR112017015206A2 (pt) 2018-06-19
US20190367518A1 (en) 2019-12-05
JP2018502077A (ja) 2018-01-25
IL253020A0 (en) 2017-08-31
IL274716A (en) 2020-07-30
CA3210320A1 (en) 2016-07-21
SG11201705678YA (en) 2017-08-30
CN113816962A (zh) 2021-12-21
IL308276A (en) 2024-01-01
CA2971460C (en) 2023-10-10
AU2020230323A1 (en) 2020-10-01
RU2017128308A (ru) 2019-02-14
WO2016115356A1 (en) 2016-07-21
ZA201704338B (en) 2023-10-25
AU2016206693A1 (en) 2017-07-13
CN107108640A (zh) 2017-08-29
SG10201906517VA (en) 2019-08-27
HK1246293A1 (zh) 2018-09-07
US20200347064A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
MX2019008815A (es) Sintesis de un inhibidor de tirosina quinasa de bruton.
BR112015021995A2 (pt) combinações de inibidores de tirosina quinase de bruton e inibidores de cyp3a4
DOP2022000096A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
PH12020552065A1 (en) Ibrutinib combination therapy
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
EA201690746A1 (ru) Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
MX2014000518A (es) Inhibidores de la tirosina quinasa de bruton.
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
EP3405192A4 (en) INHIBITORS OF BRUTON TYROSINE KINASE
EP3601264A4 (en) INHIBITORS OF BRUTON TYROSIN KINASE
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
EP3273961A4 (en) Solvated forms of a bruton's tyrosine kinase inhibitor
WO2016066726A3 (en) Active acrylamides
EP3196199A4 (en) Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor
EP3882241A4 (en) INHIBITOR OF BRUTON TYROSINE KINASE
BR112018076622A2 (pt) pirrolo[2,3-d]piridazin-4-onas e pirazolo[3,4-d]piridazin-4-onas substituídas como inibidores de proteína cinase
EP3412657A4 (en) NEW IRREVERSIBLE INHIBITOR OF BRUTON TYROSINE KINASE
EP3966204A4 (en) SUBSTITUTED 1-AMINO-1H-IMIDAZOLE-5-CARBOXAMIDE AS BRUTON TYROSINE KINASE INHIBITORS
EP4069689A4 (en) SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON TYROSINKINASE INHIBITORS
TW202419091A (zh) 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物
UY35800A (es) Combinaciones de inhibidores de la tirosina quinasa de bruton e inmunoterapias